NuVasive Inc

Most Recent

  • uploads///hospital _
    Company & Industry Overviews

    Why Globus Medical Stock Rose 10% on January 9

    On January 9, Globus Medical was trading at a stock price of $43.79, which is an ~9.91% rise from its closing price of $39.84 on January 8.

    By Daniel Collins
  • uploads///pulse trace _
    Company & Industry Overviews

    TransEnterix Stock Rose 5.41% after Its Corporate Update

    On October 1, TransEnterix stock closed at $5.64, which represents ~344.0% growth from its 52-week low of $1.27 on February 9.

    By Daniel Collins
  • uploads///hospital _
    Company & Industry Overviews

    How Wall Street Analysts View TransEnterix

    Of the five analysts tracking TransEnterix in July, two of them have recommended a “strong buy,” and one has recommended a “buy.”

    By Daniel Collins
  • uploads///q_sales
    Company & Industry Overviews

    Why Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’

    On January 9, 2018, Mizuho Securities upgraded Teva Pharmaceutical Industries (TEVA) from a “neutral” to a “buy” rating. It came after Teva announced its business restructuring plan.

    By Sarah Collins
  • uploads///Orthopedic
    Company & Industry Overviews

    Inside Johnson & Johnson’s Orthopedic Medical Devices Performance in 3Q17

    In 3Q17, JNJ hip medical devices generated revenues of $328 million, which reflected a ~2% YoY year-over-year rise and a 6% QoQ (quarter-over-quarter) rise.

    By Daniel Collins
  • uploads///revenues by segment
    Company & Industry Overviews

    Stryker Expands Its Interventional Spine Segment

    On July 11, 2017, Stryker announced that it received the FDA 510(k) clearance for its MultiGen 2 RF (radio frequency) generator.

    By Sarah Collins
  • uploads///medical device segment
    Company & Industry Overviews

    Johnson & Johnson’s Expandable Cage Acquisition to Accelerate the Spine Division

    On January 3, DePuy Synthes, a subsidiary of Johnson & Johnson (JNJ), entered into an asset purchase and development agreement with Interventional Spine.

    By Sarah Collins
  • uploads///part__q
    Earnings Report

    Why Did H.B. Fuller’s Construction Products Revenue Fall?

    H.B. Fuller’s (FUL) Construction Products segment reported revenue of $64.4 million in 3Q16, which is 12.6% of the company’s total revenue.

    By Peter Neil
  • uploads///neurotechnology and spine segmentation
    Company & Industry Overviews

    Understanding Stryker’s Neurotechnology and Spine Segment

    Stryker’s Neurotechnology and Spine segment reported an increase of 5% in net sales in 2014, driven by increased demand for neurotechnology products.

    By Sarah Collins
  • uploads///us  statistics
    Company & Industry Overviews

    How Economic and Demographic Factors Affect Medical Device Industry

    Though the medical device sector displays significant resilience towards changes in the economic environment, economic factors do impact short-term demand substantially.

    By Sarah Collins
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Nuvasive Traded above Its 100-Day Moving Average

    Nuvasive (NUVA) gained 1.3% on October 12, 2015. The stock went up on the news that the FDA gave clearance for NUVA’s cervical corpectomy cage.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.